Computational Genomics: Identifying Biomarkers for Precision Oncology
by Li Liu, PhD, Arizona State University
The Entrepreneurial Journey – James Bates, AdviNow Medical (2019)
James Bates, CEO of AdviNow Medical, shares insights on the
entrepreneurial journey at the 2019 AZBio Awards
2019 AZBio Fast Lane Award Honoree - Biosensing Instrument
a new drug is one of the most expensive and complex innovation challenges.
Biosensing Instrument, Inc. (BI), a Tempe based life science company, is
transforming early drug discovery research at pharmaceuticals and academic
laboratories around the world by enabling measurements that were not
2019 AZBio Fast Lane Award Honoree - GT Medical Technologies
400,000 Americans are newly diagnosed with some type of brain tumor each
year. For decades, clinicians have sought better treatments for these
patients that would effectively target tumor cells while preserving
healthy tissue, but to no avail. There have been few new effective
therapies over the past 30 years, and outcomes for patients have improved
very little during this time. Recurrence of brain tumors is common, and
about half of all patients treated for brain tumors have their disease
recur within a year. As a result, patients often run out of treatment
options when their tumors reoccur. GT MedTech is a medical technology
company passionately committed to improving the lives of patients with
brain tumors. This company is an excellent example of how the combination
of leading edge research and development combined with an experienced
management team can move a company forward faster.
2019 AZBio Fast Lane Award Honoree - OncoMyx Therapeutics
National Cancer Institute (NCI) estimates that there will be over 600,000
deaths from cancer in 2019. That is
roughly two percent of the U.S population.
The majority of these deaths will be caused by cancers that form
into solid tumors.
OncoMyx, a startup launched from Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have emerged as a safe and effective immuno-oncology complement. The company’s MYXV platform is poised to be a best-in-class oncolytic virus approach, and the top oncolytic virus team has assembled around MYXV to create important new therapeutic options for cancer patients. OncoMyx is currently being launched in Phoenix to test next-generation viruses in human clinical trials against a variety of human cancers.
An Extra 30 Years – Joan Koerber-Walker, AZBio (2019)
In the healthcare discussion, as we look at the value of
life science innovations, we must never forget the importance of the years.
Joan Koerber-Walker, president and CEO of the Arizona
Bioindustry Association (AZBio), leads an organization representing companies
who together employ over 300,000 Arizonans who are discovering, developing, and
delivering life science innovations that make life better in Arizona, across
the United States, and around the world.
2017 AZBio Public Service Award - Mayor Mark W. Mitchell
For his commitment to building a thriving bioscience community in Tempe and his work on behalf of life science innovators across our state, The Honorable Mark Mitchell, Mayor of the City of Tempe, Arizona is being honored with the 2017 AZBio Public Service Award.
Critical Path Institute - Data Collaboration with Global Impact
Presented by Debra Hanna, PhD
- Executive Director, Critical Path to TB Regimens (CPTR), Critical Path
Institute, and Richard Liwski – Program Director, Data Collaboration Center,
Critical Path Institute